MedTrace Logo

A Cross-sectional Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Female Participants With Epilepsy

NCT01030094 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2013-06-26

No results posted yet for this study

Summary

The purpose of this study is to investigate the influence of topiramate monotherapy on the bone and mineral metabolism markers, and bone density (the amount of mineral per square centimeter of bone ) in female participants with epilepsy (seizure disorder), before menopause (time in life when a woman stops having a menstrual period), as compared with healthy participants and comparative group received either carbamazepine or valproic acid monotherapy for at least last one year.

Conditions

Interventions

DRUG

Topiramate

This is an observational study. Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.

DRUG

Carbamazepine

This is an observational study. Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.

DRUG

Valproic acid

This is an observational study. Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.

DRUG

Normal control

This is an observational study. Healthy female participants will be observed in Normal control group.

Sponsors & Collaborators

  • Janssen Korea, Ltd., Korea

    lead INDUSTRY

Principal Investigators

  • Janssen Korea, Ltd. Clinical Trial · Janssen Korea, Ltd., Korea

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-04-30
Completion
2009-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01030094 on ClinicalTrials.gov